Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07105098 · ClinicalTrials.gov registry record · Phase 3

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

A Phase 3 study of Schizophrenia, sponsored by Neurocrine Biosciences.

Recruiting
Registry status
Phase 3
Development phase
284
Enrollment target
5
Study locations

NCT07105098 is a Phase 3 study of Schizophrenia that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 284 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (30% higher). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07105098, a Phase 3 study of Schizophrenia, is actively recruiting participants, sponsored by Neurocrine Biosciences.

RECRUITING
Registry status
Phase 3
Development phase
284 participants
Enrollment target
5
Study locations

Study Summary

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG NBI-1117568

Study Locations (5)

California

  • Neurocrine Clinical Site - Culver City
  • Neurocrine Clinical Site - Garden Grove
  • Neurocrine Clinical Site - Riverside

Georgia

  • Neurocrine Clinical Site - Atlanta

Ohio

  • Neurocrine Clinical Site - North Canton

Trial Details

FieldValue
Enrollment Target 284 participants
Start Date 2025-08-11
Est. Completion 2027-11
Phase Phase 3

Sponsor

Neurocrine Biosciences

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07105098

The ClinicalTrials.gov registry entry for NCT07105098 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (30% higher). The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07105098 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Georgia, Ohio.

Frequently Asked Questions

What is clinical trial NCT07105098 about?

NCT07105098 is a clinical study titled "NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia". The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

What is the current status of trial NCT07105098?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 284 participants. The study started on 2025-08-11. Estimated completion is 2027-11.

What conditions does trial NCT07105098 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT07105098?

The interventions under investigation include: Placebo (DRUG), NBI-1117568 (DRUG).

Who is sponsoring clinical trial NCT07105098?

This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07105098 being conducted?

This trial has 5 study locations across California, Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.